Research Topics
Genomes and GenesSpecies | Richard C DodelSummaryAffiliation: University of Bonn Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Immunotherapy for Alzheimer's diseaseRichard C Dodel
Department of Neurology, Friedrich Wilhelms University Bonn, Germany
Lancet Neurol 2:215-20. 2003..This review focuses on immunisation strategies and details of the pathways involved in antibody clearance of Abeta...- An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's diseaseCandan Depboylu
Department of Neurology, Rheinische Friedrich Wilhelms University Bonn, Bonn, Germany
Dement Geriatr Cogn Disord 17:170-3. 2004..No evidence of an earlier age at onset for carriers of the C allele was evaluated. We conclude that IL-6 (-174) polymorphism does not influence the risk of developing AD in our cohort... - The socioeconomic impact of narcolepsyRichard Dodel
Department of Neurology, Friedrich Wilhelms University Bonn, Germany
Sleep 27:1123-8. 2004..To evaluate the economic burden of patients suffering from narcolepsy... - Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's diseaseR C Dodel
Department of Neurology, Friedrich Wilhelms University, Sigmund Freudstr 25, 53105 Bonn, Germany
J Neurol Neurosurg Psychiatry 75:1472-4. 2004..This study reports the results from a pilot study using IVIgG in patients with AD... - Resource utilization and costs of stroke unit care in GermanyRichard C Dodel
Department of Neurology and Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Marburg, Germany
Value Health 7:144-52. 2004..Recently, the concept of an integrated stroke unit has been established in several countries to improve the outcome of patients. This study evaluates the costs of acute care of the different cerebrovascular insults in a stroke unit... - Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approachRichard C Dodel
Department of Neurology, Friedrich Wilhelms University, Bonn, Germany
Mov Disord 18:S52-62. 2003..These results should be adjusted to the specific setting and individual patient preferences... - Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's diseaseCandan Depboylu
Department of Neurology, Philipps University Marburg, Rudolph Bultmann Str 8, 35039 Marburg, Germany
Neurosci Lett 400:187-90. 2006..Although LRP as well as RAP seem to play an essential role in the metabolism of alpha2M and APOE, there is no increase in the genetic risk for AD in patients carrying the investigated polymorphisms... - Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's diseaseJens Carsten Moller
Department of Neurology, Philipps University, Marburg, Germany
Neurosci Lett 359:195-7. 2004..We conclude that the C/T polymorphism in the IL-1alpha promoter region at -889 does not increase the risk to develop PD... - Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's diseaseCarmen Noelker
Department of Neurology, Philipps University Marburg, Germany
Neurosci Lett 507:10-5. 2012..Further studies will be necessary on the physiological role of the identified proteins and their impact on pathways leading to neurodegeneration in PD... - Role of dopamine transporter SPECT for the practitioner and the general neurologistWolfgang H Oertel
Department of Neurology, Philipps University Marburg, Germany
Mov Disord 18:S9-15. 2003..Future studies must clarify whether it is cost effective to generously perform dopamine transporter SPECTs to minimize the time until parkinsonism can be diagnosed... - Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's diseaseCandan Depboylu
Department of Neurology, Friedrich Wilhelms University, Sigmund Freud Strasse 25, 53105, Bonn, Germany
Neurosci Lett 342:132-4. 2003..We conclude that polymorphisms in the IL-10 promoter region do not increase the risk of developing AD... - Health-related quality of life and economic burden in patients with restless legs syndromeJens P Reese
Philipps University Marburg, Department of Neurology, Rudolf Bultmannstr 8, 35039 Marburg, Germany
Expert Rev Pharmacoecon Outcomes Res 7:503-21. 2007..Very few of the RLS treatment options, however, have been evaluated for their cost-effectiveness, and further research is needed on both quality-of-life issues and the economic impact of RLS... - A polymorphism in the cystatin C promoter region is not associated with an increased risk of ADR C Dodel
Department of Neurology, Philipps-University Marburg, Germany
Neurology 58:664. 2002 - Systematic assessment of decision models in Parkinson's diseaseUwe Siebert
Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Value Health 7:610-26. 2004..We believe that structural bias could be avoided if underlying disease progression and treatment effects on symptoms are modeled separately... - Cabergoline versus levodopa monotherapy: a decision analysisAntje M Smala
Medical Economics Research Group (MERG, Munich, Germany
Mov Disord 18:898-905. 2003..Although costs were higher in patients on cabergoline, the corresponding cost-effectiveness ratio for cabergoline was at least as favourable as the ratios for many commonly accepted therapies... - NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell lineFeng Gao
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
Brain Res Mol Brain Res 105:108-14. 2002..Our data suggest that attenuation of IL-1beta-induced alpha(2)M synthesis/release by blocking NF-kappaB activation may potentially be 'protective' against the development of late-onset AD...